908 Devices Management
Management criteria checks 4/4
908 Devices' CEO is Kevin Knopp, appointed in Feb 2012, has a tenure of 14.33 years. total yearly compensation is $1.55M, comprised of 32.2% salary and 67.8% bonuses, including company stock and options. directly owns 3.54% of the company’s shares, worth $11.83M. The average tenure of the management team and the board of directors is 3.4 years and 5.3 years respectively.
Key information
Kevin Knopp
Chief executive officer
US$1.6m
Total compensation
| CEO salary percentage | 32.19% |
| CEO tenure | 14.3yrs |
| CEO ownership | 3.5% |
| Management average tenure | 3.4yrs |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
MASS: Raised 2026 Revenue Outlook Will Support A Higher Stock Price
Analysts have lifted their price target on 908 Devices stock from $10.00 to $11.00, citing updated assumptions around fair value, revenue growth, discount rate and future P/E that they consider better aligned with the company's current outlook. What’s in the News for 908 Devices 908 Devices raised its full year 2026 revenue guidance, according to a key developments summary.
MASS: Raised 2026 Revenue Outlook Will Support Higher Future P/E Multiple
Analysts have modestly adjusted their price targets on 908 Devices, reflecting updated assumptions for a fair value of $10.00, a slightly higher discount rate, marginally stronger projected revenue growth, a softer profit margin outlook, and a higher future P/E of about 70x. What's in the News 908 Devices raised its full year 2026 revenue guidance to a range of $67.0 million to $70.0 million.908 Devices Looking Better Now (Rating Upgrade)
Summary 908 Devices delivered strong Q1 results, raising full-year revenue guidance after a strategic acquisition in narcotics detection. Adjusted gross margins improved nearly three percentage points to 57%, and operating cash flow turned positive. MASS has a solid balance sheet with nearly $100 million in cash post-acquisition and is debt free, while trading at a reasonable valuation. Read the full article on Seeking AlphaMASS: Raised 2026 Revenue Guidance Will Support Higher Earnings Multiple
Analysts have reset their price target on 908 Devices to $10.00 from $8.00, citing updated assumptions around revenue growth, profitability, and future P/E that feed into a higher fair value estimate and a modestly higher discount rate. What's in the News 908 Devices raised full year 2026 revenue guidance to a range of $67.0 million to $70.0 million, compared with 2025 revenue, with the range described as representing 19% to 25% growth (Corporate Guidance: Raised).908 Devices Inc.'s (NASDAQ:MASS) 29% Price Boost Is Out Of Tune With Revenues
Those holding 908 Devices Inc. ( NASDAQ:MASS ) shares would be relieved that the share price has rebounded 29% in the...Some 908 Devices Inc. (NASDAQ:MASS) Shareholders Look For Exit As Shares Take 26% Pounding
908 Devices Inc. ( NASDAQ:MASS ) shareholders won't be pleased to see that the share price has had a very rough month...908 Devices Inc.'s (NASDAQ:MASS) Share Price Not Quite Adding Up
When close to half the companies in the Electronic industry in the United States have price-to-sales ratios (or "P/S...908 Devices Inc. (NASDAQ:MASS) Analysts Are Pretty Bullish On The Stock After Recent Results
NasdaqGM:MASS 1 Year Share Price vs Fair Value Explore 908 Devices's Fair Values from the Community and select yours...US Federal And International Funding Will Expand Global Analysis Markets
The notable increase in 908 Devices’ price target reflects improved outlook due to higher expected revenue growth and an expanded forward P/E, raising the consensus fair value from $6.50 to $9.00. What's in the News 908 Devices raised its 2025 revenue guidance to $54–56 million (13–17% growth), up from prior guidance of $53–55 million.908 Devices Inc.'s (NASDAQ:MASS) Shares Climb 26% But Its Business Is Yet to Catch Up
Despite an already strong run, 908 Devices Inc. ( NASDAQ:MASS ) shares have been powering on, with a gain of 26% in the...
The New Handheld Mass Spectrometer Launch Will Expand Market Reach
Divesting the desktop bioprocessing portfolio boosts cash reserves, streamlines operations, and is expected to enhance margins and cash flow in future years.908 Devices Makes Key Divestiture (Rating Upgrade)
Summary 908 Devices' stock surged after announcing a $70 million desktop portfolio sale, doubling its cash position and improving financial stability. The company will now focus on its handheld device business, expecting 11% to 15% revenue growth in 2025 with acceleration in 2026. MASS management believes losses will be significantly reduced with the new structure, with positive cash flow next year. Read the full article on Seeking Alpha908 Devices Inc.'s (NASDAQ:MASS) 55% Jump Shows Its Popularity With Investors
The 908 Devices Inc. ( NASDAQ:MASS ) share price has done very well over the last month, posting an excellent gain of...Earnings Update: 908 Devices Inc. (NASDAQ:MASS) Just Reported And Analysts Are Trimming Their Forecasts
The analysts might have been a bit too bullish on 908 Devices Inc. ( NASDAQ:MASS ), given that the company fell short...908 Devices: Key Investor Now Selling
Summary ARK Invest's recent sales of 908 Devices shares have helped to send the stock to multi-year lows. 908 Devices is seeing decent revenue growth, but large losses and limited financial flexibility raise concerns about future capital needs. The stock's low valuation compared to peers is a positive, but ongoing sales by ARK Invest could exert further downward pressure. Read the full article on Seeking AlphaWhy We're Not Concerned Yet About 908 Devices Inc.'s (NASDAQ:MASS) 29% Share Price Plunge
To the annoyance of some shareholders, 908 Devices Inc. ( NASDAQ:MASS ) shares are down a considerable 29% in the last...We Think 908 Devices (NASDAQ:MASS) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Investors Appear Satisfied With 908 Devices Inc.'s (NASDAQ:MASS) Prospects
When you see that almost half of the companies in the Electronic industry in the United States have price-to-sales...908 Devices Q2 2022 Earnings Preview
908 Devices (NASDAQ:MASS) is scheduled to announce Q2 earnings results on Tuesday, August 9th, before market open. The consensus EPS Estimate is -$0.26 (+3.7% Y/Y) and the consensus Revenue Estimate is $10.79M (+30.5% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 2 downward. Revenue estimates have seen 0 upward revisions and 2 downward.CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$35m |
| Dec 31 2025 | US$2m | US$500k | -US$33m |
| Sep 30 2025 | n/a | n/a | -US$73m |
| Jun 30 2025 | n/a | n/a | -US$81m |
| Mar 31 2025 | n/a | n/a | -US$57m |
| Dec 31 2024 | US$2m | US$498k | -US$53m |
| Sep 30 2024 | n/a | n/a | -US$45m |
| Jun 30 2024 | n/a | n/a | -US$28m |
| Mar 31 2024 | n/a | n/a | -US$30m |
| Dec 31 2023 | US$1m | US$475k | -US$36m |
| Sep 30 2023 | n/a | n/a | -US$39m |
| Jun 30 2023 | n/a | n/a | -US$38m |
| Mar 31 2023 | n/a | n/a | -US$37m |
| Dec 31 2022 | US$2m | US$477k | -US$34m |
| Sep 30 2022 | n/a | n/a | -US$27m |
| Jun 30 2022 | n/a | n/a | -US$26m |
| Mar 31 2022 | n/a | n/a | -US$25m |
| Dec 31 2021 | US$760k | US$400k | -US$22m |
| Sep 30 2021 | n/a | n/a | -US$29m |
| Jun 30 2021 | n/a | n/a | -US$26m |
| Mar 31 2021 | n/a | n/a | -US$18m |
| Dec 31 2020 | US$591k | US$284k | -US$13m |
| Sep 30 2020 | n/a | n/a | -US$3m |
| Jun 30 2020 | n/a | n/a | -US$6m |
| Mar 31 2020 | n/a | n/a | -US$11m |
| Dec 31 2019 | US$445k | US$287k | -US$13m |
Compensation vs Market: Kevin's total compensation ($USD1.55M) is below average for companies of similar size in the US market ($USD2.45M).
Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.
CEO
Kevin Knopp (53 yo)
Dr. Kevin J. Knopp, Ph D., Co-Founded 908 Devices Inc. in 2012 and serves as its Chief Executive Officer, President and Director since February 2012. Dr. Knopp Co-Founded Ahura Scientific, Inc. in 2002 and...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 14.3yrs | US$1.55m | 3.54% $ 11.8m | |
| Co-Founder | 14.4yrs | no data | 2.32% $ 7.7m | |
| CFO & Treasurer | 12.3yrs | US$1.14m | 0.35% $ 1.2m | |
| Chief Legal | less than a year | US$1.33m | no data | |
| Vice President of Corporate Marketing and Communications | 2.3yrs | no data | no data | |
| Senior Vice President of Sales and Product Marketing | no data | US$1.03m | 0.15% $ 511.4k | |
| Vice President of Human Resources | 4.4yrs | no data | no data | |
| Senior Vice President of Products and Production | less than a year | no data | 0.12% $ 397.6k | |
| Chief Business & Strategy Officer | less than a year | no data | no data |
Experienced Management: MASS's management team is considered experienced (3.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 14.3yrs | US$1.55m | 3.54% $ 11.8m | |
| Co-Founder | 1.3yrs | no data | 2.32% $ 7.7m | |
| Independent Director | 14yrs | US$202.51k | 0.067% $ 223.8k | |
| Independent Director | 5.3yrs | US$200.43k | 0.11% $ 361.9k | |
| Independent Chairman of the Board | 12.8yrs | US$222.51k | 1.31% $ 4.4m | |
| Independent Director | 14yrs | US$200.01k | 0.20% $ 666.1k | |
| Independent Director | 4.3yrs | US$183.34k | 0.12% $ 390.9k | |
| Independent Director | 2yrs | US$175.01k | 0.054% $ 182.0k | |
| Independent Director | less than a year | US$216.63k | 0% $ 0 |
Experienced Board: MASS's board of directors are considered experienced (5.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/21 14:14 |
| End of Day Share Price | 2026/06/18 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
908 Devices Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Puneet Souda | Leerink Partners LLC |
| Daniel Arias | Stifel, Equities Research |
| Brendan Smith | TD Cowen |